The present study involves the preparation and evaluation of floating microspheres of orlistat for improving drug bioavailability by prolongation of gastric residence time. The microspheres were prepared by a solvent diffusion–evaporation technique using inert polymers (Eudragit RL100, cellulose acetate, and ethyl cellulose). The effect of three formulation variables (i.e., drug/polymer ratio [...

BACKGROUND Little is known about how adverse events are summarised and reported in trials, as detailed information is usually considered confidential. We have acquired clinical study reports (CSRs) from the European Medicines Agency through the Freedom of Information Act. The CSRs describe the results of studies conducted as part of the application for marketing authorisation for the slimming p...

We evaluated the efficiency of a six-month outpatient weight loss treatment program combining healthy diet, fat reduction, psychological counseling, exercise, and orlistat treatment, by measuring body weight and levels of cardiovascular risk factors in 476 subjects with BMI over 30 or 28 with increased blood pressure, cholesterol, and sugar at the baseline and at the end of program. After four ...

BACKGROUND The quality of harms reporting in journal publications is often poor, which can impede the risk-benefit interpretation of a clinical trial. Clinical study reports can provide more reliable, complete, and informative data on harms compared to the corresponding journal publication. This case study compares the quality and quantity of harms data reported in journal publications and clin...

BACKGROUND Obesity is a major world-wide epidemic which has led to a surge of various weight loss-inducing medical or surgical treatments. Orlistat is a gastrointestinal lipase inhibitor used as an adjunct treatment of obesity and type 2 diabetes mellitus to induce clinically significant weight loss via fat malabsorption. CASE PRESENTATION We describe a case of a 76-year-old female with past ...

s 1. Little, J.L., Fels D.R., Koumenis, C., and Kridel, S.J., (2005) Orlistat induces ER stress in prostate tumor cells. American Association for Cancer Research (AACR). Anaheim, California. 2. Little, J.L., Wheeler, F.B., Fels, D.R., Koumenis, C., and Kridel, S.J. Inhibition of fatty acid synthase induces ER stress-dependent cell death. American Association for Cancer Research (AACR), Washingt...